US · XNCR · BIOTECHNOLOGY
Xencor, Inc. (XNCR) intrinsic value and stock valuation
$33.26as of 2026-11-21 · Mkt cap 1.47B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Xencor, Inc. DCF and intrinsic value
InvestorsCraft values XNCR with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from XNCR’s statements →
Xencor, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $125.6M | $110.5M | $174.6M | $164.6M | $275.1M |
| Operating income | -$-177.5M | -$-178.41M | -$-132.36M | -$-82.47M | $43.8M |
| Net income | -$-91.92M | -$-232.62M | -$-133.13M | -$-55.18M | $82.6M |
| EPSd | -$-1.24M | -$-3.58M | -$-2.2M | -$-925.06K | $1.37M |
| Operating cash flow | -$-135.12M | -$-202.19M | -$-77.93M | $24.5M | -$-16.85M |
| Capital expenditure | -$-3.15M | -$-6.1M | -$-18.45M | -$-43.4M | -$-15.98M |
| Free cash flow | -$-138.27M | -$-208.28M | -$-96.37M | -$-18.92M | -$-32.83M |
| Total assets | $875.5M | $952M | $952.7M | $846.3M | $838.2M |
| Total debt | $187.8M | $232M | $83.4M | $59.6M | $34M |
| Net debt | $133.7M | $191.1M | $29.6M | $5.69M | -$-109.51M |
| Total equity | $635.6M | $674M | $669.1M | $727.5M | $733.5M |
| Cash and short-term investments | $547.7M | $497.8M | $593.7M | $623.1M | $334.1M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $125.6M | $110.5M | $174.6M | $164.6M | $275.1M |
| Cost of revenue | $10.5M | $227.7M | $0.00 | $199.6M | $192.5M |
| Gross profit | $115.1M | -$-117.19M | $174.6M | -$-34.98M | $82.6M |
| Research and development expenses | $239.4M | $227.7M | $253.6M | $199.6M | $192.5M |
| Selling, general and administrative expenses | $63.6M | $58.9M | $53.4M | $47.5M | $38.8M |
| Other expenses | -$-10.51M | -$-225.36M | $0.00 | -$-199.56M | -$-192.51M |
| Operating expenses | $292.6M | $61.2M | $307M | $47.5M | $38.8M |
| Cost and expenses | $303.1M | $288.9M | $307M | $247.1M | $231.3M |
| Interest income | $27.5M | $31.9M | $18.6M | $4.82M | $860K |
| Interest expense | $31.9M | $36.6M | $0.00 | $0.00 | $10K |
| Depreciation and amortization | $10.5M | $12.1M | $11.5M | $8.8M | $7.49M |
| Ebitda | -$-46.98M | -$-186.17M | -$-101.96M | -$-45.7M | $90.1M |
| Operating income | -$-177.5M | -$-178.41M | -$-132.36M | -$-82.47M | $43.8M |
| Total other income/expenses, net | $87.9M | -$-56.52M | $12.7M | $28M | $38.9M |
| Income before tax | -$-89.42M | -$-234.92M | -$-119.63M | -$-54.51M | $82.6M |
| Income tax expense | $2.5M | $1.62M | $13.7M | $670K | $0.00 |
| Net income | -$-91.92M | -$-232.62M | -$-133.13M | -$-55.18M | $82.6M |
| Weighted average shares outstanding | $74.2M | $65M | $60.5M | $59.7M | $58.4M |
| Weighted average diluted shares outstanding | $74.2M | $65M | $60.5M | $59.7M | $60.5M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $547.7M | $497.8M | $593.7M | $623.1M | $334.1M |
| Net receivables | $29.3M | $60.9M | $11.3M | $29M | $66.4M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $599.8M | $577.6M | $623.2M | $675.3M | $424.4M |
| Property, plant and equipment, net | $90.9M | $98.1M | $100.1M | $93.6M | $60M |
| Goodwill and intangible assets | $8.38M | $18.5M | $18.7M | $18.5M | $16.5M |
| Long-term investments | $175.9M | $256.8M | $209.7M | $58.2M | $331.7M |
| Total non-current assets | $275.7M | $374.3M | $329.5M | $170.9M | $413.8M |
| Total assets | $875.5M | $952M | $952.7M | $846.3M | $838.2M |
| Accounts payable | $10.8M | $16.8M | $13.9M | $10.1M | $14M |
| Short-term debt | $46.5M | $51.5M | $9.77M | $4.71M | $0.00 |
| Deferred revenue | $0.00 | $0.00 | $31.7M | $30.3M | $37.3M |
| Total current liabilities | $95.9M | $87.4M | $84.7M | $63.8M | $70.7M |
| Long-term debt | $141.2M | $180.5M | $73.7M | $54.9M | $34M |
| Deferred revenue, non-current | $0.00 | $0.00 | $125.2M | $0.00 | $0.00 |
| Total non-current liabilities | $144M | $190.5M | $198.9M | $54.9M | $34M |
| Capital lease obligations | $68M | $68.4M | $62.5M | $59.6M | $34M |
| Total liabilities | $239.9M | $277.9M | $283.6M | $118.8M | $104.7M |
| Common stock | $720K | $700K | $610K | $600K | $590K |
| Retained earnings | -$-795.96M | -$-704.04M | -$-464.37M | -$-338.29M | -$-283.1M |
| Accumulated other comprehensive income (loss) | $1.58M | -$-660K | $1.29M | -$-6.95M | -$-1.51M |
| Total equity | $635.6M | $674M | $669.1M | $727.5M | $733.5M |
| Total investments | $669.6M | $713.7M | $749.7M | $627.3M | $522.4M |
| Total debt | $187.8M | $232M | $83.4M | $59.6M | $34M |
| Net debt | $133.7M | $191.1M | $29.6M | $5.69M | -$-109.51M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-91.92M | -$-236.54M | -$-133.13M | -$-55.18M | $82.6M |
| Depreciation and amortization | $10.5M | $12.1M | $11.5M | $8.8M | $7.49M |
| Stock-based compensation | $43.2M | $53.3M | $0.00 | $48.9M | $37M |
| Change in working capital | $47.5M | -$-40.4M | $19.1M | $48.9M | -$-102.6M |
| Accounts receivable | $28.7M | -$-32.67M | $19.8M | $36.9M | -$-54.94M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $1.4M |
| Accounts payable | -$-3.95M | $2.85M | $3.83M | -$-3.91M | $5.05M |
| Net cash provided by operating activities | -$-135.12M | -$-202.19M | -$-77.93M | $24.5M | -$-16.85M |
| Investments in property, plant and equipment | -$-3.15M | -$-6.1M | -$-21.25M | -$-38.49M | -$-15.98M |
| Acquisitions, net | $0.00 | $0.00 | $500K | $0.00 | -$-2.66M |
| Net cash used for investing activities | $140M | -$-7.87M | -$-110.56M | -$-119.72M | -$-46.25M |
| Common stock issued | $9.96M | $201.3M | $5.39M | $0.00 | $28.9M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $8.23M | $197.2M | $188.7M | $5.7M | $43M |
| Net change in cash | $13.1M | -$-12.91M | -$-150K | -$-89.54M | -$-20.06M |
| Cash at end of period | $54.4M | $41.3M | $53.8M | $53.9M | $143.5M |
| Operating cash flow | -$-135.12M | -$-202.19M | -$-77.93M | $24.5M | -$-16.85M |
| Capital expenditure | -$-3.15M | -$-6.1M | -$-18.45M | -$-43.4M | -$-15.98M |
| Free cash flow | -$-138.27M | -$-208.28M | -$-96.37M | -$-18.92M | -$-32.83M |
Line items
Line items
Line items
About Xencor, Inc.
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.
- CEO
- Bassil I. Dahiyat
- Employees
- 260
- Beta
- 0.86
Included in
Explore
Frequently asked questions
What is the intrinsic value of Xencor, Inc. (XNCR)?
Xencor, Inc. (XNCR) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is XNCR undervalued?
XNCR trades at a price of $33.26 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.